[go: up one dir, main page]

WO2001088162A3 - Methods and vectors for generating antibodies in avian species and uses therefor - Google Patents

Methods and vectors for generating antibodies in avian species and uses therefor Download PDF

Info

Publication number
WO2001088162A3
WO2001088162A3 PCT/US2001/014817 US0114817W WO0188162A3 WO 2001088162 A3 WO2001088162 A3 WO 2001088162A3 US 0114817 W US0114817 W US 0114817W WO 0188162 A3 WO0188162 A3 WO 0188162A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
processes
relates
methods
avian species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/014817
Other languages
French (fr)
Other versions
WO2001088162A2 (en
Inventor
Lingxun Duan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GenWay Biotech Inc
Original Assignee
GenWay Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/573,442 external-priority patent/US6951742B1/en
Application filed by GenWay Biotech Inc filed Critical GenWay Biotech Inc
Priority to AU2001259631A priority Critical patent/AU2001259631A1/en
Publication of WO2001088162A2 publication Critical patent/WO2001088162A2/en
Publication of WO2001088162A3 publication Critical patent/WO2001088162A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/20—Heterogeneous data integration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Databases & Information Systems (AREA)
  • Analytical Chemistry (AREA)
  • Bioethics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to processes for producing polyclonal and monoclonal antibodies to an antigen in an avian species, preferably in a chicken, using polynucleotide vaccination. The present invention also relates to processes for determining the proteomics profile of a set of pre-selected DNA sequences isolated from a bio-sample, preferably the proteomics profile of a human cDNA library. The present invention additionally relates to processes for identifying physiologically distinguishable markers associated with a physiologically abnormal bio-sample. The present invention further relates to antibody arrays, integrated databases for identification of genes and proteins, multi-functional gene expression vectors, and methods of producing and using such antibody arrays, integrated databases and multi-functional gene expression vectors.
PCT/US2001/014817 2000-05-16 2001-05-07 Methods and vectors for generating antibodies in avian species and uses therefor Ceased WO2001088162A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001259631A AU2001259631A1 (en) 2000-05-16 2001-05-07 Methods and vectors for generating antibodies in avian species and uses therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20489900P 2000-05-16 2000-05-16
US60/204,899 2000-05-16
US09/573,442 2000-05-16
US09/573,442 US6951742B1 (en) 1998-11-16 2000-05-16 Methods and vectors for generating antibodies in avian species and uses therefor

Publications (2)

Publication Number Publication Date
WO2001088162A2 WO2001088162A2 (en) 2001-11-22
WO2001088162A3 true WO2001088162A3 (en) 2002-09-19

Family

ID=26899888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014817 Ceased WO2001088162A2 (en) 2000-05-16 2001-05-07 Methods and vectors for generating antibodies in avian species and uses therefor

Country Status (2)

Country Link
AU (1) AU2001259631A1 (en)
WO (1) WO2001088162A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003054021A2 (en) * 2001-12-20 2003-07-03 Agricultural Research Council Semi-synthetic antibody fragment combinatorial library based on avian immunoglobulin genes
CN1818651B (en) * 2006-03-13 2010-07-21 东北农业大学 Rabbit Anti-Goose IgY+IgY(△Fc)(H+L) Horseradish Peroxidase Labeled Antibody
MX2011001930A (en) * 2008-08-29 2011-04-21 Symphogen As Method for cloning avian-derived antibodies.
EP3255146B1 (en) 2009-03-16 2019-05-15 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
EP2414513B1 (en) 2009-03-31 2015-10-28 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
CN103118692A (en) 2010-04-26 2013-05-22 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
EP2563936B1 (en) 2010-04-29 2018-03-14 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
CN103118693B (en) 2010-04-29 2017-05-03 Atyr 医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
CN103097523B (en) 2010-04-29 2016-09-28 Atyr医药公司 The innovation for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of Asparaginyl-tRNA synthetase finds
AU2011248355B2 (en) 2010-05-03 2017-01-19 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases
WO2011140135A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
ES2623805T3 (en) 2010-05-03 2017-07-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic and antibody compositions related to phenylalanyl-alpha-tRNA synthetase protein fragments
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
WO2011143482A2 (en) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
WO2011146410A2 (en) 2010-05-17 2011-11-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
CA2800375C (en) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
WO2011153277A2 (en) 2010-06-01 2011-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
CN103118695B (en) 2010-07-12 2016-08-03 Atyr医药公司 Discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of glycyl-tRNA synthetase
US9029506B2 (en) 2010-08-25 2015-05-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases
JP6039656B2 (en) 2011-06-01 2016-12-07 メディカル プログノシス インスティテュート エー／エス Method and apparatus for predicting prognosis of cancer recurrence
DK2814514T3 (en) 2012-02-16 2017-12-18 Atyr Pharma Inc Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases
NZ709167A (en) 2012-11-27 2020-03-27 Univ Pontificia Catolica Chile Compositions and methods for diagnosing thyroid tumors
WO2014195032A1 (en) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
DK3169815T3 (en) 2014-07-15 2021-02-15 Ontario Institute For Cancer Res METHODS AND DEVICES FOR PREDICTING THE EFFICIENCY OF ANTHRACYCLINE TREATMENT
GB2579856A (en) * 2018-12-18 2020-07-08 Emergex Vaccines Holding Ltd MHC Class I associated peptides for prevention and treatment of hepatitis B virus infection
WO2021205408A1 (en) * 2020-04-10 2021-10-14 Igy Immune Technologies And Life Sciences Inc. Igy immunoglobulins targeting coronavirus, methods of preparing same, and methods of using same
CN117821469B (en) * 2023-11-22 2024-08-02 扬州大学 Application of chicken TRIM45 truncated recombinant protein or polyclonal antibody thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024268A1 (en) * 1993-04-14 1994-10-27 Arthur Webster Pty. Ltd. Recombinant avian adenovirus vector
WO2000029444A1 (en) * 1998-11-16 2000-05-25 Genway Biotech, Inc. Generation of antibodies using polynucleotide vaccination in avian species

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024268A1 (en) * 1993-04-14 1994-10-27 Arthur Webster Pty. Ltd. Recombinant avian adenovirus vector
WO2000029444A1 (en) * 1998-11-16 2000-05-25 Genway Biotech, Inc. Generation of antibodies using polynucleotide vaccination in avian species

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROLLIER CHRISTINE ET AL: "Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection.", JOURNAL OF VIROLOGY, vol. 74, no. 10, May 2000 (2000-05-01), pages 4908 - 4911, XP002192933, ISSN: 0022-538X *
SAKAGUCHI M ET AL: "Protection of chickens from Newcastle disease by vaccination with a linear plasmid DNA expressing the F protein of Newcastle disease virus", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 14, no. 8, 1 June 1996 (1996-06-01), pages 747 - 752, XP004069557, ISSN: 0264-410X *

Also Published As

Publication number Publication date
AU2001259631A1 (en) 2001-11-26
WO2001088162A2 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
WO2001088162A3 (en) Methods and vectors for generating antibodies in avian species and uses therefor
ITRM930301A1 (en) PROCEDURE FOR THE PREPARATION OF IMMUNOGEN AND DIAGNOSTIC REAGENTS, AND IMMUNOGEN AND DIAGNOSTIC REAGENTS SO OBTAINABLE.
EP1616876A3 (en) A method for identification, isolation and production of antigens to a specific pathogen
US8241894B2 (en) Method for analyzing proteins
WO2004001381A8 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
WO2003099999A3 (en) Generation and selection of protein library in silico
ATE439380T1 (en) METHODS FOR PRODUCING HUMAN MONOCLONAL ANTIBODIES
ATE282717T1 (en) NOVEL METHOD FOR IDENTIFYING CLONES WITH A DESIRED BIOLOGICAL PROPERTY, STARTING FROM AN EXPRESSION GENE BANK
DE602004018388D1 (en) PROTEIN PHOSPHORYLING IN BULK-CELL ANAPLASTIC LYMPHOMA
BR9915732A (en) Antibody generation using polynucleotide vaccination in bird species
WO2000073430A3 (en) Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
EP2275435A3 (en) Streptococcus agalactiae antigens I + II
Todd et al. The immunogenicity and antigenicity of proteins
WO1999036568A3 (en) Method for identifying t-cell stimulating protein fragments
PH12021550470A1 (en) Improved anti-flt3 antigen binding proteins
WO1999000671A3 (en) Method for identification of tumor antigens with autoantibodies in serum
DE69829587D1 (en) NUCLEIC ACID MOLECULES CORRELATING WITH THE WEAK RHESUS-D PHENOTYP
WO2001085989A3 (en) Hypha-specific factors from candida albicans
WO2003091700A3 (en) Epitope mapping using nuclear magnetic resonance
WO2003042366A3 (en) A novel saitohin gene and uses of same
WO2002000829A3 (en) A novel peptide--- human ftsh protein 16.83 and the polynucleotide coding this novel peptide
WO2000034294A3 (en) Tumor necrosis factor receptor homologue-1 ('trh1')
WO2001059114A3 (en) Tumor suppressor gene, p47ing3
Lin-Fa et al. Use of a gene-targeted phage display random epitope library to map an antigenic determinant on the bluetongue virus outer capsid protein VP5
EP1597383A4 (en) Variants of cytochrome c and methods of diagnosis of thrombocytopenia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP